OBJECTIVES: This study aimed to measure the treatment patterns and clinical characteristics of Colombian patients with metastatic non-small cell lung cancer in one HMO between

METHODS: It is an observational, descriptive, retrospective study which collected the information in one Health Management Organization (HMO) in Colombia from patients with diagnosis of metastatic non-small cells lung cancer (NSCLC) between 2018 to 2022. Electronic healthcare reports were used to identify the patients and collect data. International code diseases version 10 was used to identify patients. The index date is defined as the time when the patient is diagnosed with NSCLC. The abstracted data collected were demographic and clinical characteristics, and treatments.

RESULTS: Five hundred eighty-nine patients met the inclusion and exclusion criteria. Mean age was 66.9 years old (Standard deviation (SD) 11.3). The female patients were 54.2%. The mean body mass index was 24 (SD 4.6) with active smoking at the diagnosis period of 32.1%. Approximately, 90% of patients were diagnosed with lung cancer in stage IV followed by 7.5% in IIIB and 3.5% in IIB and IIIA. Histologically, adenocarcinoma was reported in 78% of patients and squamous in 12%. About 89.3% patients had between 1 or 2 metastases at diagnosis. Brain (25.6%), respiratory system (22.0%), and bone (17.0%) were the main sites of metastasis. Around 30% patients were biomarker testingbeing more frequent EGFR (45%) and PD-L1 (40.5%). In first line for adenocarcinoma, chemotherapy was used in 71.1%, targeted therapy was 31.1%, and immunotherapy 16.4%. This distribution changed by biomarkers increasing the proportion of target therapy. While in squamous, chemotherapy was used in 95.5%.

CONCLUSIONS: The first diagnosis of Metastatic NSCLC patients was in later stage of lung cancer, adenocarcinoma being the most common. Target therapy was the strategy most used in the first line in the treatment of adenocarcinoma NSCLC.